The treatment of relapsed or refractory intermediate grade non-Hodgkin's lymphoma with autologous bone marrow transplantation followed by cyclosporine and interferon

Bone Marrow Transplantation

Volumn 19, Issue 3, 1997, Pages 221-226

  Gryn, J ^a,b   Johnson, E ^a   Goldman, N ^a   Devereux, L ^a   Grana, G ^a   Hageboutros, A ^a   Fernandez, E ^a   Constantinou, C ^a   Harrer, W ^a   Viner, E ^a   Goldberg, J ^a  

^a Division of Female Pelvic Medicine and Reconstructive Surgery   (United States)

^b Department of Medicine ^*  (United States)

Author keywords

Graft versus host disease; Marrow transplantation; Non Hodgkin's lymphoma

Indexed keywords

ALPHA INTERFERON; CARMUSTINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ETOPOSIDE; INTERFERON;

ADULT; AGED; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CANCER GRADING; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DEATH; ERYTHEMA; FEMALE; GRAFT VERSUS HOST REACTION; HEMORRHAGIC CYSTITIS; HUMAN; HYPERBILIRUBINEMIA; INTRAVENOUS DRUG ADMINISTRATION; MALE; MUCOSA INFLAMMATION; NONHODGKIN LYMPHOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENCE RISK; RISK FACTOR; SKIN BIOPSY; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTE; VEIN OCCLUSION;

EID: 0031039725     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1700646     Document Type: Article

References (30)

1. Phillip T, Armitage JO, Spitzer G et al. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. New Engl J Med 1987; 316: 1493-1498.
2. Phillips GL, Fay JW, Herzig RH et al. The treatment of progressive non-Hodgkin's lymphoma with intensive chemoradiotherapy and autologous marrow transplantation. Blood 1990; 75: 831-838.
3. Gulati S, Yahalom J, Acaba L et al. Treatment of patients with relapsed and resistant non-Hodgkin's lymphoma using total body irradiation, etoposide, and cyclophosphamide and autologous bone marrow transplantation. J Clin Oncol 1992; 10: 936-941.
4. Jones R, Ambinder R, Piantadosi S, Santos G. Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation. Blood 1991; 77: 649-653.
5. Ratanatharathorn V, Uberti J, Karanes C et al. Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin's lymphoma. Blood 1994; 84: 1050-1055.
6. Horowitz M, Gale R, Sondel P et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555-562.
7. Glazier A, Tutschka P, Farmer E, Santos G. Graft-vs-host disease in cyclosporine A treated rats following syngeneic and autologous bone marrow reconstitution. J Exp Med 1983; 158: 1-8.
8. Geller R, Esa A, Beschorner W et al. Successful in vitro graft-vs-tumor effect against Ia-bearing tumor using cyclosporine-induced graft-vs-host disease in the rat. Blood 1989; 74: 1165-1171.
9. Kennedy M, Vogelsang G, Beveridge R et al. Phase I trial of intravenous cyclosporine to induce graft-vs-host disease in women undergoing autologous bone marrow transplantation for breast cancer. J Clin Oncol 1993; 11: 478-484.
10. Slymen D, Miller T, Lippman S et al. Immunobiologic factors predictive of clinical outcome in diffuse large-cell lymphoma. J Clin Oncol 1990; 8: 986-993.
11. McDonald G, Sharma P, Matthews D et al. The clinical course of 53 patients with veno-occlusive disease of the liver after marrow transplantation. Transplantation 1985; 36: 603-608.
12. Canellos GP. Residual mass in lymphoma may not be residual disease. J Clin Oncol 1988; 6: 931-933.
13. Kaplan E, Meier P. Non-parametric estimation from incomplete observation. J Am Stat Assoc 1958; 53: 457-481.
14. Fefer A, Benyunes M, Massumoto C et al. Interleukin-2 therapy after autologous bone marrow transplantation for hematologic malignancies. Semin Oncol 1993; 20: (Suppl. 9): 41-45.
15. Klingemann H, Grigg A, Wilkie-Boyd K et al. Treatment with recombinant interferon (alpha-2b) early after bone marrow transplantation in patients at high risk for relapse. Blood 1991; 78: 3306-3311.
16. Weisdorf D, Anderson P, Blazar B et al. Interleukin 2 immediately after autologous bone marrow transplantation for acute lymphoblastic leukemia - a phase I study. Transplantation 1993; 55: 61-66.
17. Gryn J, Goldberg J, Johnson E et al. The effect of IL-2 on autologous graft-vs-host disease. Proc ASCO 1994; 13: 1241a.
18. Grossbard ML, O'Day S, Gribben J et al. Anti-B4 blocked ricin (anti-B4-BR) therapy following autologous bone marrow transplantation (ABMT) for B-cell non-Hodgkin's lymphoma (B-NHL): update of phase I/II trials. Blood 1993; 82: 1759a.
19. Wheeler C, Antin J, Churchill W et al. Cyclophosphamide, carmustine and etoposide with autologous bone marrow transplantation in refractory Hodgkin's disease and non-Hodgkin's lymphoma: a dose-finding study. J Clin Oncol 1990; 8: 648-656.
20. Stone R, Neuberg D, Soiffer R et al. Myelodysplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol 1994; 12: 2535-2542.
21. Hess A, Fischer A, Horwitz L et al. Characterization of peripheral autoregulatory mechanisms that prevent development of cyclosporin-induced syngeneic graft-versus-host disease. J Immunol 1994; 153: 400-411.
22. Kennedy M, Vogelsang G, Jones R et al. Phase I trial of interferon gamma to potentiate cyclosporine-indueed graft-versus-host disease in women undergoing autologous hone marrow transplantation for breast cancer. J Clin Oncol 1994; 12: 249-257
23. Ratanatharathorn V, Uberti J, Karanes C et al. Phase I study of alpha-interferon augmentation of cyclosporine-induced graft-vs-host disease in recipients of autologous hone marrow transplantation. Bone Marrow Transplant 1994; 13: 625-630.
24. Gryn J, Goldberg J, Johnson E. Autologous graft-vs-host disease using cyclosporine and interferon post-marrow transplant. Exp Hematol 1993; 21: 190a.
25. Beyer J, Schwerdtfeger R, Siegert W. Graft-versus-host disease or graft-versus-host-like syndrome. Blood 1992; 80: 2948-2949.
26. Mazumder A, Verma U, Areman E et al. Peripheral blood stem cell transplantation in breast cancer patients with interleukin-2 activated PBSC leads to visceral graft-vs-host disease. Proc ASCO 1994; 13: 91a.
27. Cahill R, Verma U, Areman E et al. IL-2-activated bone marrow transplantation in patients with advanced hematologic malignancies: induction of autologous graft-vs-host disease. Blood 1994; 84: 2891a.
28. Livesey S, Holmes J, Whittaker J. Ocular complications of bone marrow transplantation. Eye 1989; 3: 271-276.
29. Jabs D, Wingard J, Green W et al. The eye in bone marrow transplantation. III. Conjunctival graft-vs-host disease. Arch Ophthalmol 1989; 107: 1343-1348.
30. Wheeler C, Strawderman M, Ayash L et al. Prognostic factors for treatment outcome in autotransplantation of intermediate-grade and high-grade non-Hodgkin's lymphoma with cyclophosphamide, carmustine, and etoposide. J Clin Oncol 1993; 11: 1085-1091.